S, M. J., M, D., N, D., M, T., D, A. K., K, H., . . . F, M. F. (2026). Health technology assessment reports for oncology medications in Canada from 2018 to 2025: Methodological critiques on manufacturers' submissions and a comparison between manufacturers and Canada's Drug Agency (CDA) analyses. Expert review of pharmacoeconomics & outcomes research, 26(3), 451. https://doi.org/10.1080/14737167.2026.2632265
Chicago Style (17th ed.) CitationS, Mardani Jadid, Dokhaei M, Dini N, Tajadod M, Azizi Khezri D, Hariri K, Levine M, and Mirzayeh Fashami F. "Health Technology Assessment Reports for Oncology Medications in Canada from 2018 to 2025: Methodological Critiques on Manufacturers' Submissions and a Comparison Between Manufacturers and Canada's Drug Agency (CDA) Analyses." Expert Review of Pharmacoeconomics & Outcomes Research 26, no. 3 (2026): 451. https://doi.org/10.1080/14737167.2026.2632265.
MLA (9th ed.) CitationS, Mardani Jadid, et al. "Health Technology Assessment Reports for Oncology Medications in Canada from 2018 to 2025: Methodological Critiques on Manufacturers' Submissions and a Comparison Between Manufacturers and Canada's Drug Agency (CDA) Analyses." Expert Review of Pharmacoeconomics & Outcomes Research, vol. 26, no. 3, 2026, p. 451, https://doi.org/10.1080/14737167.2026.2632265.
